Nitric-oxide based nonsteroidal anti-inflammatory agents

Drug Discovery Today: Therapeutic Strategies

Volumn 3, Issue 3, 2006, Pages 395-400

  Ongini, Ennio ^a   Bolla, Manlio ^a  

^a Nicox Research Institute   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ACETYLSALICYLIC ACID DERIVATIVE; CYCLOOXYGENASE 2 INHIBITOR; CYCLOOXYGENASE INHIBITING NITRIC OXIDE DONOR; DIAZENIUMDIOLATE DERIVATIVE; DICLOFENAC DERIVATIVE; FLURBIPROFEN; FLURBIPROFEN 4 NITROXYBUTYL ESTER; FURAZOLIDONE; GLYCERYL TRINITRATE; INDOMETACIN DERIVATIVE; ISOSORBIDE DINITRATE; NAPROXCINOD; NAPROXEN; NITRIC ESTER DERIVATIVE; NITRIC OXIDE; NITRIC OXIDE DONOR; NITRONAPROXEN; NMI 1182; NONSTEROID ANTIINFLAMMATORY AGENT; PRODRUG; PROSTAGLANDIN SYNTHASE INHIBITOR; ROFECOXIB; UNCLASSIFIED DRUG; VALDECOXIB;

ANGINA PECTORIS; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; DIGESTIVE SYSTEM INJURY; DISEASE EXACERBATION; DRUG CLASSIFICATION; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; GASTROINTESTINAL HEMORRHAGE; GASTROINTESTINAL MUCOSA; GASTROINTESTINAL SYMPTOM; GASTROINTESTINAL TRACT; HEART INFARCTION; HUMAN; HYPERTENSION; INFLAMMATION; NONHUMAN; OSTEOARTHRITIS; OSTEOARTHROPATHY; PAIN; REVIEW; STROKE; STRUCTURE ACTIVITY RELATION; VASCULAR ENDOTHELIUM;

EID: 33751172951     PISSN: 17406773     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ddstr.2006.09.004     Document Type: Review

References (43)

1. Vane J.R., and Botting R.M. Mechanism of action of nonsteroidal anti-inflammatory drugs. Am. J. Med. 104 (1998) 2S-8S
2. Flower R.J. The development of COX-2 inhibitors. Nat. Rev. Drug Discov. 2 (2003) 179-191
3. Ardoin S.P., and Sundy J.S. Update on nonsteroidal anti-inflammatory drugs. Current Opinion Rheumatology 18 (2006) 221-226
4. Moncada S., and Higgs A. The l-arginine-nitric oxide pathway. N. Engl. J. Med. 329 (1993) 2002-2012
5. Ignarro L.J. Nitric oxide as a unique signalling molecule in the vascular system: a historical overview. J. Physiol. Pharmacol. 53 (2002) 503-514
6. Reynaert N.L., et al. Nitric oxide represses inhibitory kappaB kinase through S-nitrosylation. Proc. Natl. Acad. Sci. U S A 101 (2004) 8945-8950
7. Patel R.P., et al. Mechanisms of the pro- and antioxidant actions of nitric oxide in atherosclerosis. Cardiovasc. Res. 18 (2000) 465-474
8. Elliott S.N., and Wallace J.L. Nitric oxide: a regulator of mucosal defense and injury. J. Gastroenterol. 33 (1998) 792-803
9. Wallace J.L., and Del Soldato P. The therapeutic potential of NO-NSAIDs. Fundam. Clin. Pharmacol. 17 (2003) 11-20
10. Schnitzer T.J., et al. Comparison of the COX-inhibiting nitric oxide donator AZD3582 and rofecoxib in treating the signs and symptoms of osteoarthritis of the knee. Arthritis Rheum. 53 (2005) 827-837
11. Naseem K.M. The role of nitric oxide in cardiovascular diseases. Mol. Aspects Med. 26 (2005) 33-65
12. Morphy R., and Rankovic Z. Designed multiple ligands. An emerging drug discovery paradigm. J. Med. Chem. 48 (2005) 6523-6543
13. Brown J.F., et al. Nitric oxide donors increase mucus gel thickness in rat stomach. Eur. J. Pharmacol. 223 (1992) 103-104
14. Kubes P., et al. Nitric oxide: an endogenous modulator of leukocyte adhesion. Proc. Natl. Acad. Sci. U S A 88 (1991) 4651-4655
15. Wallace J.L., et al. Gastric ulceration induced by nonsteroidal anti-inflammatory drugs is a neutrophil-dependent process. Am. J. Physiol. 259 (1990) G462-G467
16. Muscara M.N., and Wallace J.L. Nitric Oxide. V. Therapeutic potential of nitric oxide donors and inhibitors. Am. J. Physiol. 276 (1999) G1313-G1336
17. Miyoshi M., et al. Dietary nitrate inhibits stress-induced gastric mucosal injury in the rat. Free Radic. Res. 37 (2003) 85-90
18. Barrachina M.D., et al. Transdermal nitroglycerin prevents nonsteroidal anti-inflammatory drug gastropathy. Eur. J. Pharmacol. 281 (1995) R3-R4
19. Lanas A., et al. Nitrovasodilators, low-dose aspirin, other nonsteroidal anti-inflammatory drugs, and the risk of upper gastrointestinal bleeding. N. Engl. J. Med. 343 (2000) 834-839
20. Gasco A., et al. Focus on recent approaches for the development of new NO-donors. Mini Rev. Med. Chem. 5 (2005) 217-229
21. Tomisato W., et al. Low direct cytotoxicity and cytoprotective effects of nitric oxide releasing indomethacin. Dig. Dis. Sci. 50 (2005) 1927-1937
22. Somasundaram S., et al. Intestinal tolerability of nitroxybutyl-flurbiprofen in rats. Gut 40 (1997) 608-613
23. Davies N.M., et al. NO-naproxen vs. naproxen: Ulcerogenic, analgesic and anti-inflammatory effects. Aliment. Pharmacol. Ther. 11 (1997) 69-79
24. Fiorucci S., et al. Nitric oxide (NO)-releasing naproxen (HCT-3012 [(S)-6-methoxy-alpha-methyl-2-naphthaleneacetic Acid 4-(nitrooxy)butyl ester]) interactions with aspirin in gastric mucosa of arthritic rats reveal a role for aspirin-triggered lipoxin, prostaglandins, and NO in gastric protection. J. Pharmacol. Exp. Ther. 311 (2004) 1264-1271
25. Hawkey C.J., et al. Gastrointestinal safety of AZD3582, a cyclooxygenase inhibiting nitric oxide donator: proof of concept study in humans. Gut 52 (2003) 1537-1542
26. Lohmander L.S., et al. A randomised, placebo controlled, comparative trial of the gastrointestinal safety and efficacy of AZD3582 versus naproxen in osteoarthritis. Ann. Rheum. Dis. 64 (2005) 449-456
27. Young D.V., et al. A comparison of the cyclooxygenase inhibitor-NO donors (CINOD), NMI-1182 and AZD3582, using in vitro biochemical and pharmacological methods. Biochem. Pharmacol. 70 (2005) 1343-1351 Erratum in: Biochem Pharmacol. (2006) 28, 711
28. Ellis J.L., et al. NMI-1182, a gastro-protective cyclo-oxygenase-inhibiting nitric oxide donor. Inflammopharmacology 12 (2005) 521-534
29. Rudd M.A., et al. Nitric oxide and hypertension. In: Loscalzo J., and Vita J.A. (Eds). Contemporary Cardiology, Nitric Oxide and the Cardiovascular System (2000), Humana Press 227-246
30. Stokes G.S., et al. Long-term effectiveness of extended-release nitrates for the treatment of systolic hypertension. Hypertension 45 (2005) 380-384
31. Salpeter S.R., et al. Meta-analysis: cardiovascular events associated with nonsteroidal anti-inflammatory drugs. Am. J. Med. 119 (2006) 552-559
32. Wilson S.L., and Poulter N.R. The effect of nonsteroidal anti-inflammatory drugs and other commonly used non-narcotic analgesics on blood pressure level in adults. J. Hypertens. 24 (2006) 1457-1469
33. Kearney P.M., et al. Do selective cyclo-oxygenase-2 inhibitors and traditional nonsteroidal anti-inflammatory drugs increase the risk of atherothrombosis? Meta-analysis of randomized trials. BMJ 332 (2006) 1302-1308
34. Chobanian A.V., et al. The seventh report of the joint national committee on preventio detection, evaluation, and treatment of high blood pressure. The JNC7 Report. JAMA 289 (2003) 2560-2572
35. Muscara M.N., et al. Antihypertensive properties of a nitric oxide-releasing naproxen derivative in two-kidney, one-clip rats. Am. J. Physiol. Heart Circ. Physiol. 279 (2000) H528-H535
36. Muscara M.N., et al. Effect of a nitric oxide-releasing naproxen derivative on hypertension and gastric damage induced by chronic nitric oxide inhibition in the rat. Life Sci. 62 (1998) PL235-PL240
37. Presotto C. et al. (2006) HCT 3012 reduces blood pressure in the spontaneously hypertensive rat model. 70th Am. Coll. Rheumatol. Annual Meeting, 10-15 November 2006, Washington, DC, USA (Abstract)
38. Schnitzer T. et al. (2004) AZD3582, a CINOD, differs significantly from rofecoxib in having a neutral effect on blood pressure in patients with osteoarthritis: results of a randomized control trial. 68th ACR/ARHP Annual Scientific Meeting, 16-21 October 2004, San Antonio, Texas, USA (Abstract)
39. Capone M.L., et al. Clinical pharmacology of plateled, monocyte, and vascular cyclooxygenase inhibiton by naproxen and low-dose aspirin in healty subjects. Circulation 109 (2004) 1468-1471
40. Engelhardt F.C., et al. Synthesis of a NO-releasing prodrug of rofecoxib. J. Org. Chem. 71 (2006) 480-491
41. Lolli M.L., et al. A new class of ibuprofen derivatives with reduced gastrotoxicity. J. Med. Chem. 44 (2001) 3463-3468
42. Bandarage U.K., et al. Nitrosothiol esters of diclofenac: synthesis and pharmacological characterization as gastrointestinal-sparing prodrugs. J. Med. Chem. 43 (2000) 4005-4016
43. Velázquez C.A. et al. (2004) Novel NO-NO-NSAIDs Possessing a nitric oxide donor diazeniumdiolate moiety. Nitr. Oxide 14, A50 (Abstract P104).